Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03004287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Oct 2026 → Oct 2027
See other at-risk trials from University of Arkansas

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Oct 2026 to Oct 2027
    • Study completion pushed from Oct 2027 to Oct 2028
    • Eligibility criteria expanded, about 18 words
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date: Oct 2025 to Oct 2026
    • Study completion date: Oct 2026 to Oct 2027
    v15
  3. Primary completion date: Oct 2024 to Oct 2025
    • Study completion date: Oct 2025 to Oct 2026
    v14
  4. Primary completion date: Oct 2023 to Oct 2024
    • Study completion date: Oct 2024 to Oct 2025
    v13
  5. 2 versions Re-verified since Sep 1, 2022, no change to tracked fieldsv11-v12
Show 9 earlier versionsHide 9 earlier versions
  1. Primary completion date: Oct 2021 to Oct 2023
    • Study completion date: Oct 2021 to Oct 2024
    v10
  2. Primary and study completion dates: Jan 2021 to Oct 2021
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v9
  3. Site contact updatedv8
  4. 2 versions Re-verified since Jul 13, 2018, no change to tracked fieldsv6-v7
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v5
  6. Start date: Jun 1, 2017 to Jul 1, 2017v4
  7. Start date: May 1, 2017 to Jun 1, 2017
    • Study sites: 0 to 1
    v3
  8. Start date: Jan 2017 to May 1, 2017v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
Trial Details
NCT Number NCT03004287
Lead Sponsor University of Arkansas
Collaborators: Janssen, LP
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov